Azithromycin dosage forms with reduced side effects
US6984403B2 · kind B2 · utility
60Cited by
115References
48Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 23, 2004 |
| Grant date | Jan 10, 2006 |
| Priority date | — |
| Expiry date | Feb 14, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P33/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is related to an oral dosage form comprising an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a glyceride which comprises glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate, or a mixture thereof and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.